MKKS — McKusick-Kaufman Syndrome Regulator

The MKKS gene, also known as BBS6, provides essential instructions for making a protein that acts like a cellular chaperone. Just as a chaperone guides and protects, the MKKS protein helps other proteins fold into their correct shapes so they can work properly. It is particularly important during early development, helping to form the limbs, heart, and reproductive system. Additionally, it plays a key role in the function of cilia, which are tiny, hair-like structures on cells that act like antennas, sensing signals from the environment. In the eyes, these cilia are crucial for the cells that detect light, allowing us to see. When the MKKS gene is mutated, the chaperone protein cannot do its job correctly. This can lead to two main conditions: McKusick-Kaufman syndrome (MKS) and Bardet-Biedl syndrome (BBS). MKS primarily affects physical development before birth, leading to extra fingers or toes, heart defects, and reproductive system abnormalities. BBS is a more severe condition that includes the features of MKS but also causes progressive vision loss (often starting with night blindness), obesity, kidney problems, and learning difficulties. The vision loss happens because the light-sensing cells in the retina slowly break down when their cilia don't work properly. Both MKS and BBS are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the MKKS gene—one from each parent—to develop the condition. The parents, who each carry one mutated copy, typically do not show any symptoms and are known as carriers. For families with a history of these conditions, genetic testing can help identify the specific mutations, providing a clear diagnosis and helping to guide medical care and family planning.

Gene description: Encodes a chaperonin-like protein involved in cilia formation and function, often associated with Bardet-Biedl syndrome.

Patient and family guide: The MKKS gene, also known as BBS6, provides essential instructions for making a protein that acts like a cellular chaperone. Just as a chaperone guides and protects, the MKKS protein helps other proteins fold into their correct shapes so they can work properly. It is particularly important during early development, helping to form the limbs, heart, and reproductive system. Additionally, it plays a key role in the function of cilia, which are tiny, hair-like structures on cells that act like antennas, sensing signals from the environment. In the eyes, these cilia are crucial for the cells that detect light, allowing us to see. When the MKKS gene is mutated, the chaperone protein cannot do its job correctly. This can lead to two main conditions: McKusick-Kaufman syndrome (MKS) and Bardet-Biedl syndrome (BBS). MKS primarily affects physical development before birth, leading to extra fingers or toes, heart defects, and reproductive system abnormalities. BBS is a more severe condition that includes the features of MKS but also causes progressive vision loss (often starting with night blindness), obesity, kidney problems, and learning difficulties. The vision loss happens because the light-sensing cells in the retina slowly break down when their cilia don't work properly. Both MKS and BBS are inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the MKKS gene—one from each parent—to develop the condition. The parents, who each carry one mutated copy, typically do not show any symptoms and are known as carriers. For families with a history of these conditions, genetic testing can help identify the specific mutations, providing a clear diagnosis and helping to guide medical care and family planning.

Gene function: MKKS encodes a protein involved in the assembly and function of cilia, which are crucial for various cellular processes, including photoreceptor outer segment development and signaling. In the retina, dysfunctional cilia lead to impaired phototransduction and cellular homeostasis. Mutations in MKKS are associated with ciliopathies, resulting in retinal degeneration as a key feature.

Protein structure: The MKKS gene encodes a protein of 570 amino acids that belongs to the type II chaperonin family. Structurally, it shares significant homology with the alpha subunit of the thermosome found in archaea. The protein is characterized by its ability to form complex, multi-subunit ring structures that create a central cavity where target proteins can fold in an isolated environment. This folding process is driven by the binding and hydrolysis of ATP, which induces conformational changes in the chaperonin complex. In human cells, the MKKS protein does not act alone but assembles with other chaperonin-like proteins, such as BBS10 and BBS12, to form a specialized complex. This complex interacts with the CCT/TRiC chaperonin machinery to mediate the assembly of the BBSome, a highly conserved octameric protein complex. The proper formation and function of the BBSome are entirely dependent on the structural integrity of the MKKS protein, and mutations that alter its structure, solubility, or stability directly impair BBSome assembly and ciliary transport.

Molecular function: The MKKS gene encodes a protein that functions as a probable molecular chaperone, sharing sequence similarity with the type II chaperonin family. Its primary biochemical activity involves assisting in the folding of target proteins, a process that is dependent on ATP hydrolysis. This chaperonin function is critical for maintaining protein homeostasis within the cell, ensuring that newly synthesized or misfolded proteins achieve their correct functional conformations. At the cellular level, MKKS is a centrosome-shuttling protein that plays a vital role in the assembly of the BBSome, a multi-protein complex essential for ciliary function. The BBSome mediates the transport of vesicles and proteins to and from the primary cilium, a sensory organelle present on most mammalian cells. In the retina, this transport mechanism is crucial for the movement of phototransduction proteins across the connecting cilium of photoreceptor cells. Additionally, MKKS is implicated in nuclear-cytoplasmic transport, specifically aiding in the delivery of the chromatin remodeling protein SMARCC1 into the nucleus, which is important for regulating gene expression during early development.

Expression pattern: The MKKS gene is broadly expressed across various human adult and fetal tissues, reflecting its fundamental role in cellular function and development. High levels of expression are noted in the brain, endocrine system, respiratory system, and the developing limbs, heart, and reproductive organs. This widespread expression pattern aligns with the multisystemic nature of the diseases associated with MKKS mutations, such as Bardet-Biedl syndrome and McKusick-Kaufman syndrome. In the context of the retina, MKKS is expressed in photoreceptor cells, where it plays a crucial role in the maintenance and function of the connecting cilium. The expression of MKKS in these sensory cells is essential for the proper transport of proteins required for phototransduction. The loss of MKKS expression or function in the retina leads to the progressive photoreceptor degeneration characteristic of Bardet-Biedl syndrome.

Mutation spectrum: The mutation spectrum of the MKKS gene includes a variety of pathogenic variants, such as missense, nonsense, frameshift, and splice-site mutations. Frameshift and nonsense mutations, which typically result in a truncated and non-functional protein, are frequently associated with the more severe Bardet-Biedl syndrome (BBS) phenotype. Missense mutations, which may only partially impair protein function, can lead to either BBS or the less severe McKusick-Kaufman syndrome (MKS), depending on their specific impact on the protein's structure and stability. A notable hotspot for MKKS mutations is found within the Old Order Amish population, where a specific founder allele containing two missense mutations in cis (p.His84Tyr and p.Ala242Ser) is highly prevalent and responsible for the majority of MKS cases in this group. Outside of this population, mutations are more diverse and distributed throughout the gene. The total number of known pathogenic variants continues to grow as genetic testing becomes more widespread, contributing to our understanding of the mutational landscape of MKKS-related disorders.

Pathogenic variants: 1. p.His84Tyr (c.250C>T) - A missense mutation that, when present in cis with p.Ala242Ser, is the primary cause of McKusick-Kaufman syndrome in the Old Order Amish population. 2. p.Ala242Ser (c.724G>T) - A missense mutation that co-occurs with p.His84Tyr on the Amish founder allele, contributing to the MKS phenotype. 3. p.Tyr37Cys (c.110A>G) - A missense mutation associated with Bardet-Biedl syndrome, known to cause increased degradation and reduced solubility of the MKKS protein. 4. p.Gly345Glu (c.1034G>A) - A missense mutation that leads to rapid degradation of the MKKS protein via the ubiquitin-proteasome pathway, resulting in BBS. 5. c.2111_2112del - A 2-bp deletion resulting in a frameshift and premature protein truncation, identified in non-Amish patients with MKS and BBS.

Clinical significance: Mutations in the MKKS gene are clinically significant as they are the primary cause of McKusick-Kaufman syndrome (MKS) and a subset of Bardet-Biedl syndrome (BBS), specifically BBS6. MKS is characterized by a triad of features: hydrometrocolpos (in females), postaxial polydactyly, and congenital heart disease. It is typically diagnosed at birth or in early infancy. The severity of MKS can vary, but it is generally considered a developmental disorder with specific structural anomalies. In contrast, BBS6 is a multisystem disorder that includes the features of MKS but also presents with progressive retinal dystrophy, obesity, intellectual disability, and renal malformations. The retinal dystrophy in BBS typically begins with night blindness in childhood, progressing to peripheral vision loss and eventually legal blindness by the second or third decade of life. The clinical manifestation of MKKS mutations thus spans a spectrum from the primarily structural defects of MKS to the progressive, multisystemic degeneration seen in BBS, highlighting the gene's critical role in both development and cellular maintenance.

Inheritance: Autosomal Recessive

Chromosomal location: 20p12.3

Genotype-phenotype correlations: Genotype-phenotype correlations for the MKKS gene are complex and highlight the variable expressivity of its mutations. The most striking correlation is observed in the Old Order Amish population, where homozygosity for two specific missense variants in cis (p.His84Tyr and p.Ala242Ser) consistently results in McKusick-Kaufman syndrome (MKS). This specific combination of variants appears to cause a partial loss of function that primarily affects early development, leading to the structural anomalies of MKS without the progressive degeneration seen in Bardet-Biedl syndrome (BBS). Conversely, mutations that result in a more severe or complete loss of MKKS function, such as frameshift or nonsense mutations, are typically associated with the broader and more severe phenotype of BBS. These mutations disrupt the protein's ability to fold target proteins or participate in the BBSome complex, leading to the multisystemic features of BBS, including retinal dystrophy and obesity. Furthermore, the presence of mutations in other BBS genes can modify the phenotype, suggesting an oligogenic model of inheritance in some cases, where the severity of the disease is influenced by the total mutational burden across multiple loci.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies that can cure or halt the progression of the retinal dystrophy or other systemic features caused by MKKS mutations. Management is primarily supportive and focuses on treating the specific symptoms as they arise. This includes surgical correction of anatomical defects in McKusick-Kaufman syndrome, such as hydrometrocolpos and congenital heart defects. For Bardet-Biedl syndrome, management involves rigorous weight control, management of diabetes and hypertension, and educational support. Regular ophthalmologic evaluations are crucial to monitor the progression of retinal degeneration, and patients are often provided with low-vision aids and mobility training. In the realm of investigational therapies, gene therapy holds significant promise for inherited retinal diseases, including those caused by MKKS mutations. While a specific gene therapy for MKKS (BBS6) is not yet in advanced clinical trials, the success of Luxturna (voretigene neparvovec-rzyl) for RPE65-mediated retinal dystrophy has paved the way for similar approaches. Preclinical studies using viral vectors to deliver functional copies of BBS genes to the retina in animal models have shown potential in preserving photoreceptor function. Additionally, targeted therapies addressing the obesity component of BBS, such as setmelanotide (an MC4R agonist), have shown efficacy in clinical trials and are being evaluated for broader use in BBS patients.

Diagnostic testing: Diagnostic testing for MKKS mutations typically involves molecular genetic testing, often as part of a multigene panel for ciliopathies or inherited retinal diseases. This approach is preferred because the clinical features of McKusick-Kaufman syndrome and Bardet-Biedl syndrome overlap significantly with other genetic conditions. Next-generation sequencing (NGS) panels can efficiently screen MKKS alongside other BBS-associated genes. In cases where a specific founder mutation is suspected, such as in the Amish population, targeted testing for known variants (e.g., p.His84Tyr and p.Ala242Ser) may be performed. Genetic counseling is a critical component of the diagnostic process. Since both MKS and BBS are inherited in an autosomal recessive manner, parents of an affected individual are typically obligate carriers, and there is a 25% recurrence risk for future pregnancies. Counselors must navigate the complex genotype-phenotype correlations, particularly the potential for a child diagnosed with MKS to later develop the progressive features of BBS. Prenatal testing and preimplantation genetic testing are available for families with known MKKS mutations.

Animal models: The primary animal models used to study MKKS function are mouse models, specifically Mkks knockout (Mkks-/-) mice. These mice display a phenotype that closely resembles human Bardet-Biedl syndrome, including retinal degeneration, obesity, increased food intake, hypoactivity, and increased blood pressure. The retinal degeneration in these mice is characterized by photoreceptor cell loss, which has been instrumental in understanding the role of MKKS in maintaining retinal integrity. Zebrafish models have also been utilized to study the function of MKKS, particularly its role in nuclear-cytoplasmic transport and early development. Knockdown of MKKS in zebrafish leads to developmental defects that can be rescued by wild-type human MKKS, demonstrating the conserved function of this chaperonin across species. These models have been crucial in elucidating the interaction between MKKS and other proteins, such as SMARCC1, and their role in ciliary function and development.

Population genetics: The population genetics of the MKKS gene are most notably characterized by a strong founder effect in the Old Order Amish population of North America. In this group, a specific allele containing two missense mutations (p.His84Tyr and p.Ala242Ser) is highly prevalent, leading to a significantly increased incidence of McKusick-Kaufman syndrome compared to the general population. Outside of the Amish community, MKKS mutations are rare, and the carrier frequency in the general population is low. However, mutations in MKKS are estimated to account for approximately 4% to 11% of all cases of Bardet-Biedl syndrome globally, making it a significant contributor to the overall mutational burden of this rare disorder.

Selected references: 1. Stone DL, et al. Mutation of a gene encoding a putative chaperonin causes McKusick-Kaufman syndrome. Nat Genet, 2000. PMID: 10802661 2. Katsanis N, et al. Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. Nat Genet, 2000. PMID: 10973251 3. Slavotinek AM, et al. Mutations in MKKS cause Bardet-Biedl syndrome. Nat Genet, 2000. PMID: 10973252 4. Hirayama S, et al. MKKS is a centrosome-shuttling protein degraded by disease-causing mutations via CHIP-mediated ubiquitination. Mol Biol Cell, 2008. PMID: 18094050 5. Seo S, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. Proc Natl Acad Sci U S A, 2010. PMID: 20080638 6. Scott CA, et al. Nuclear/cytoplasmic transport defects in BBS6 underlie congenital heart disease through perturbation of a chromatin remodeling protein. PLoS Genet, 2017. PMID: 28753628 7. Forsyth RL, et al. Bardet-Biedl Syndrome Overview. GeneReviews, 2023. PMID: 20301537